All articlesResearch6 min read
Research

The 2026 Peptide Regulatory Tracker

Where every major peptide stands with the FDA in 2026, from the Category 2 list to the July PCAC review.

By the pru team  ·  Updated July 9, 2026  ·  6-minute read
A calm young professional reading a regulatory document on a laptop by a bright window, focused and at ease
Image: pru

2026 is a turning point for compounded peptides. On April 15, the FDA removed 12 peptides from its 503A Category 2 list, and its advisory committee reviews 7 of them on July 23 and 24. None of it makes peptides illegal to prescribe through a licensed pharmacy. This tracker maps where each peptide stands, and updates as the FDA acts.

The 2026 peptide status board

12
peptides came off the 503A Category 2 list on April 15, 2026
7
under PCAC review on July 23 to 24, 2026; 5 more at a Feb 2027 meeting
not a ban
coming off Category 2 is a status reset, not a ban or an approval
still legal
prescribed peptides are legal through a licensed 503A pharmacy
PeptideCategory2026 statusAt pru
BPC-157RecoveryOff Category 2, under PCAC reviewPlanned
TB-500RecoveryOff Category 2, under PCAC reviewPlanned
KPVGut / recoveryOff Category 2, under PCAC reviewPlanned
MOTS-cLongevity / metabolicOff Category 2, under PCAC reviewPlanned
DSIPSleepOff Category 2, under PCAC reviewPlanned
SemaxCognitionOff Category 2, under PCAC reviewPlanned
EpitalonLongevityOff Category 2, under PCAC reviewPlanned
GHK-Cu (injectable)Recovery / skinOff Category 2, under Feb 2027 PCAC reviewPlanned (cream sold now)
Compounded semaglutideWeight lossCompoundable by prescriptionLive
Compounded tirzepatideWeight lossCompoundable by prescriptionLive
PT-141Sexual healthCompoundable by prescriptionLive
SermorelinMuscle / GHCompoundable by prescriptionLive
NAD+LongevityCompoundableLive
GlutathioneAntioxidantCompoundable by prescriptionLive
Peptide regulatory status, July 2026. Source: FDA notices and PCAC agenda.

What the 2026 changes mean

Here is the exciting part: for the first time, a real path is forming for the FDA to let pharmacies compound peptides like BPC-157 and TB-500. Coming off Category 2 does not add a peptide to the authorized 503A list or make it FDA-approved.

It resets each one to a pending state while the FDA takes a closer look, in two waves: seven on July 23-24, 2026 (BPC-157, TB-500, KPV, MOTS-c, DSIP, semax, epitalon), and five more, including injectable GHK-Cu, at a second PCAC meeting slated before the end of February 2027.

Keep the shape of the July vote in mind. PCAC is a panel of independent experts, and it votes on whether each peptide should be eligible for 503A compounding based on the specific medical uses it was nominated for, not broad wellness or anti-aging claims.

The vote is a recommendation, not a ruling. The FDA weighs it, decides on its own, and is not bound by it. A yes is not approval, does not place a peptide on the list by itself, and does not move it to Category 1.

After the meeting, the FDA runs its own review and the required steps, which can take many months. So the door is opening, it just is not open yet, and that is a real turning point worth being excited about.

Through all of it, the 503A framework for compounding a prescription for one patient stayed in place. That is how pru operates: a licensed physician confirms fit, and an FDA-registered 503A pharmacy compounds what is prescribed. pru is preparing to offer these peptides the right way the moment the path is real.

Common questions

Are peptides legal in 2026?
Yes, prescribed peptides remain legal to compound and fill through a licensed 503A pharmacy. The 2026 FDA changes reset some peptides to a pending review state, but they did not make peptides illegal.
Which peptides is the FDA reviewing in July 2026?
The Pharmacy Compounding Advisory Committee reviews 7 peptides on July 23 to 24, 2026: BPC-157, TB-500, KPV, MOTS-c, DSIP, Semax, and Epitalon. It is an exciting step, and the committee's vote is a recommendation to the FDA, which then decides on its own.
Does coming off Category 2 mean a peptide is banned?
No. Removal from the 503A Category 2 list is a status change, not a ban and not an FDA approval. It moves the peptide to a pending state pending further review.
How does pru keep peptides affordable?
pru runs on an at-cost model. You pay one flat membership, and the medication is passed through at the pharmacy's price with no member markup. Because pru never marks the medication up, we have every reason to push its price down, not up. As pru grows and orders more, we negotiate lower pricing with our partner pharmacies, and those savings go straight to you. Healthcare pricing is usually hidden and inflated; pru is built to sit on your side of it: transparent, at cost, and fighting to make peptides more affordable as we scale.
Do the savings add up if I take more than one peptide?
Yes, and this is where pru's at-cost pricing saves you the most. Because pru never marks the medication up, every vial is priced at cost, so each peptide you add avoids the markup a typical provider builds in. If a physician has you on more than one peptide, or on a stack, that saving repeats on every vial, all under one flat $50 membership instead of a marked-up price on each. The more your protocol includes, the more the difference adds up, which makes doing it the right way a financially responsible choice, not an expensive one.
Sources & further reading
  1. FDA 503A bulk drug substances notices and PCAC meeting agenda, 2026.
  2. Compiled by pru; updated as the FDA acts.

Want more like this?

Subscribe to get new articles delivered to your inbox. No spam, unsubscribe anytime.

All Articles

The blog

Stay in the loop.

Evidence-based insights on peptide therapy, longevity, and health optimization, delivered straight to your inbox. No spam, unsubscribe anytime.